Absence of Significant Drug-Drug Interactions Between Next Generation Direct Acting Antivirals ABT-493 and ABT-530 and Methadone or Buprenorphine/Naloxone in Subjects on Opioid Maintenance Therapy ..... "no dose adjustments required"

Conference Reports for NATAP

66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015


Absence of Significant Drug-Drug Interactions Between Next Generation Direct Acting Antivirals ABT-493 and ABT-530 and Methadone or Buprenorphine/Naloxone in Subjects on Opioid Maintenance Therapy ..... "no dose adjustments required"

	Reported by Jules Levin AASLD 2015 Nov 13-17 San Francisco, CA Matthew P. Kosloski, Sandeep Dutta, Weihan Zhao, Armen Asatryan, Jens Kort, Wei Liu AbbVie Inc., North Chicago, Illinois, United States